Spots Global Cancer Trial Database for atra
Every month we try and update this database with for atra cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer | NCT01048645 | Non-Small-Cell ... | ATRA PLACEBO | 18 Years - 80 Years | National Institute of Cancerología | |
| A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00136461 | Acute Myelogeno... Myelodysplastic... | All-trans retin... Bryostatin 1 | 18 Years - | Dana-Farber Cancer Institute | |
| Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker | NCT01041833 | Non Small Cell ... | atRA Placebo | 18 Years - 80 Years | National Institute of Cancerología | |
| Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer | NCT00100906 | Kidney Cancer | IL-2 ATRA | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Acute Promyelocytic Leukemia 2006 (APL) | NCT00378365 | Leukemia, Promy... | Arsenic trioxid... ATRA | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Phase IIb Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer | NCT04241276 | Pancreatic Canc... | ATRA Gemcitabine nab-paclitaxel | 16 Years - | Queen Mary University of London | |
| All-trans Retinoic Acid, and Arsenic +/- Idarubicin | NCT00413166 | Acute Promyeloc... | All-Trans Retin... Arsenic Trioxid... Idarubicin Gemtuzumab Ozog... | - | M.D. Anderson Cancer Center | |
| Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer | NCT01048645 | Non-Small-Cell ... | ATRA PLACEBO | 18 Years - 80 Years | National Institute of Cancerología | |
| Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | NCT00675870 | Acute Promyeloc... | NRX 195183 Soft... | 18 Years - | NuRx Pharmaceuticals, Inc. | |
| Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy | NCT01404949 | Acute Promyeloc... | Tretinoin and A... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II 5-Azacytidine Plus VPA Plus ATRA | NCT00326170 | Myelodysplastic... Acute Myelogeno... | 5-Azacytidine (... Valproic Acid All-Trans Retin... | 3 Years - | M.D. Anderson Cancer Center | |
| Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML | NCT05654194 | Acute Myeloid L... | Azacitidine Com... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) | NCT02177812 | Leukaemia, Myel... | GSK2879552 ATRA | 18 Years - | GlaxoSmithKline | |
| ATRA, Celecoxib, and Itraconazole as Maintenance | NCT02401295 | Relapsed Multip... | ATRA Celecoxib Itraconazole | 18 Years - 75 Years | University of Iowa | |
| A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00136461 | Acute Myelogeno... Myelodysplastic... | All-trans retin... Bryostatin 1 | 18 Years - | Dana-Farber Cancer Institute | |
| ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells | NCT00400556 | Multiple Myelom... Cutaneous Lymph... | ATRA plus G-CSF... | 18 Years - 70 Years | Peter MacCallum Cancer Centre, Australia | |
| A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | NCT02200978 | Childhood Acute... | ATO RIF ATRA mitoxantrone Ara-C MTX 6MP intrathecal inj... | - 16 Years | South China Children's Leukemia Group | |
| Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | NCT01226303 | Acute Promyeloc... | ATRA ATRA + IDA | - 21 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | NCT01987297 | Acute Promyeloc... | ATRA+Arsenic ATRA+Chemo | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | NCT01987297 | Acute Promyeloc... | ATRA+Arsenic ATRA+Chemo | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) | NCT00504764 | Acute Promyeloc... | Arsenic Trioxid... Autologous Tran... Allogenic Trans... ATRA | 18 Years - | PETHEMA Foundation | |
| Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | NCT00675870 | Acute Promyeloc... | NRX 195183 Soft... | 18 Years - | NuRx Pharmaceuticals, Inc. | |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS | NCT00439673 | Myelodysplastic... | 5-Azacytidine Valproic Acid ATRA | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL | NCT00520208 | Acute Promyeloc... | Tamibarotene | 18 Years - | CytRx | |
| Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | NCT04305041 | Melanoma | Pembrolizumab Quavonlimab Vibostolimab Lenvatinib ATRA | 18 Years - 120 Years | Merck Sharp & Dohme LLC | |
| ATRA, Celecoxib, and Itraconazole as Maintenance | NCT02401295 | Relapsed Multip... | ATRA Celecoxib Itraconazole | 18 Years - 75 Years | University of Iowa | |
| APL93: Timing of CxT and Role of Maintenance | NCT00599937 | Leukemia, Promy... | ATRA ATRA and or Che... | - | Groupe d'etude et de travail sur les leucemies aigues promyelocytaires | |
| Acute Promyelocytic Leukemia 2006 (APL) | NCT00378365 | Leukemia, Promy... | Arsenic trioxid... ATRA | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | NCT00408278 | Acute Promyeloc... | ATRA Idarubicina Mitoxantrone ARA-C | - 75 Years | PETHEMA Foundation | |
| Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | NCT01226303 | Acute Promyeloc... | ATRA ATRA + IDA | - 21 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Stromal TARgeting for PAncreatic Cancer (STAR_PAC) | NCT03307148 | Pancreatic Aden... | ATRA Gemcitabine Nab-paclitaxel | 18 Years - | Barts & The London NHS Trust | |
| Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy | NCT01404949 | Acute Promyeloc... | Tretinoin and A... | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
